Treatment options for hepatitis B

被引：2

作者：

Conly, J. M. ^{[1
,2
,3
]}

Johnston, B. L. ^{[4
,5
]}

机构：

[1] Univ Calgary, Dept Med, Calgary, AB, Canada

[2] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada

[3] Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB, Canada

[4] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

来源：

CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY | 2007年 / 18卷 / 03期

关键词：

D O I：

10.1155/2007/464652

中图分类号：

R51 [传染病];

学科分类号：

100401 [流行病与卫生统计学];

摘要：

[No abstract available]

引用

页码：173 / 176

页数：4

共 31 条

[1]

[Anonymous], FIELDS VIROLOGY

[2]

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B (vol 39, pg 595, 2003) [J].

Boni, C ;

Penna, A ;

Bertoletti, A ;

Lamonaca, V ;

Rapti, I ;

Missale, G ;

Pilli, M ;

Urbani, S ;

Cavalli, A ;

Cerioni, S ;

Panebianco, R ;

Jenkins, J ;

Ferrari, C .

JOURNAL OF HEPATOLOGY, 2004, 40 (06) :1053-1054

[3]

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [J].

Boni, C ;

Bertoletti, A ;

Penna, A ;

Cavalli, A ;

Pilli, M ;

Urbani, S ;

Scognamiglio, P ;

Boehme, R ;

Panebianco, R ;

Fiaccadori, F ;

Ferrari, C .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :968-975

[4]

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B [J].

Boni, C ;

Penna, A ;

Bertoletti, A ;

Lamonaca, V ;

Rapti, I ;

Missale, G ;

Pilli, M ;

Urbani, S ;

Cavalli, A ;

Cerioni, S ;

Panebianco, R ;

Jenkins, J ;

Ferrari, C .

JOURNAL OF HEPATOLOGY, 2003, 39 (04) :595-605

[5]

Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) [J].

Chang, T. T. ;

Shiftman, M. L. ;

Tong, M. ;

Liaw, Y. F. ;

Komolmit, P. ;

Sorbel, J. ;

Arterburn, S. ;

Mondou, E. ;

Chuck, S. ;

Marcellin, P. .

JOURNAL OF HEPATOLOGY, 2006, 44 :S187-S187

[6]

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].

Chang, TT ;

Gish, RG ;

de Man, R ;

Gadano, A ;

Sollano, J ;

Chao, YC ;

Lok, AS ;

Han, KH ;

Goodman, Z ;

Zhu, J ;

Cross, A ;

DeHertogh, D ;

Wilber, R ;

Colonno, R ;

Apelian, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010

[7]

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].

Chen, CJ ;

Yang, HI ;

Su, J ;

Jen, CL ;

You, SL ;

Lu, SN ;

Huang, GT ;

Iloeje, UH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73

[8]

CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333

[9]

Colonno R, 2005, HEPATOLOGY, V42, p573A

[10]

Colonno RJ, 2006, HEPATOLOGY, V44, p229A

← 1 2 3 4 →